Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are scheduled to have a sentinel lymph node biopsy at the same time as, or after, breast surgery
- People who have signed and dated a consent form before the study procedures begin
Who may not be able to join:
- People who are pregnant or currently breastfeeding
- People who have a condition involving too much iron in the body
- People with a known allergy or sensitivity to iron, dextran compounds, or blue dye
- People who are unable to understand the information provided about the study, give consent, or take part in the study procedures
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Fredrik Wärnberg, Sahlgrenska University Hospital
Phone: +4631823931
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
SLN detection rate for Magtrace 0.1 ml and for dual technique (Tc99 +/- blue dye) measured as per cent of patients where a SLN is identified using either the magnetic or the dual technique.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.